BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include ORLADEYO, an oral serine protease inhibitor for HAE, and peramivir injection (marketed as RAPIVAB, RAPIACTA, and PERAMIFLU), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza. The company also has a pipeline of investigational drugs, such as Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE currently in Phase 3 trials; BCX17725, a protein therapeutic for Netherton syndrome in Phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema in Phase 1; and STAR-0310, a monoclonal antibody OX40 antagonist for atopic dermatitis in Phase 1a.

BioCryst Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol BCRX. Its shares are traded in United States Dollars (USD). As a US-based company, its financial reporting and stock trading are conducted in USD, making it accessible to investors on major US exchanges.

BioCryst Pharmaceuticals operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This classification reflects its focus on developing and commercializing specialty pharmaceutical products, particularly for rare diseases like hereditary angioedema (HAE) and influenza. As a biotechnology company, it engages in research, development, and manufacturing of both branded and generic-like treatments, with a pipeline targeting unmet medical needs in niche therapeutic areas.

BioCryst Pharmaceuticals is headquartered in Durham, North Carolina, United States. The company primarily serves the US market but also has international reach through collaborations and in-license relationships with partners such as Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation. Additionally, it has agreements with government entities like the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority (BARDA), as well as academic institutions such as Albert Einstein College of Medicine. Its products, including peramivir for influenza, are marketed globally under various brand names.

BioCryst Pharmaceuticals generates revenue primarily through the commercialization of its approved drugs. Its key revenue driver is ORLADEYO (berotralstat), an oral treatment for hereditary angioedema (HAE). Additionally, the company earns revenue from peramivir injection, an influenza treatment sold under the names RAPIVAB, RAPIACTA, and PERAMIFLU. BioCryst also benefits from collaborations and licensing agreements with partners such as Torii Pharmaceutical, Shionogi, and Green Cross Corporation, which may provide milestone payments and royalties. The company's pipeline, including Navenibart (Phase 3 for HAE) and other early-stage candidates, represents potential future revenue streams if approved.